NUV-1511
Advanced Solid Tumors
Phase 1Active
Key Facts
About Nuvation Bio
Nuvation Bio is a mission-driven oncology company focused on developing next-generation therapies for cancers with high unmet need, aiming to improve efficacy and reduce side effects. A key inflection point was achieved in 2025 as the company transitioned to commercial-stage status, celebrating at the NYSE. Its strategy leverages founder David Hung's proven track record, a hybrid pipeline built on proprietary discovery and strategic acquisitions, and a global operational footprint. The company is now positioned to build a sustainable oncology franchise.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |